Latest Breaking News On - Wakefulness test - Page 1 : comparemela.com

TAK-861 Shows Promise in Phase 2b Narcolepsy Type 1 Trial

TAK-861 demonstrated significant and sustained improvements in the treatment of narcolepsy type 1 in a phase 2b clinical trial.

Alkermes to Present Data for ALKS 2680 in Narcolepsy Treatment

Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.

Alkermes plc: Alkermes to Present New Clinical Data for ALKS 2680 at SLEEP 2024

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

Takeda Pharmaceutical : FY2023 (April 2023-March 2024) Quarter 4 Quarterly Financial Report

Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024

BOSTON and LONDON, April 22, 2024 Centessa Pharmaceuticals plc , a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today.